Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases
Diseases [C] » Endocrine System Diseases [C19] » Gonadal Disorders » Ovarian Diseases
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases
Hierarchy View
Subtype Terms (8)
Anovulation
20 drugs (16 approved, 4 experimental)
Menopause, Premature
5 drugs (3 approved, 2 experimental)
Oophoritis
2 approved drugs
Ovarian Cysts
12 drugs (10 approved, 2 experimental)
Ovarian Hyperstimulation Syndrome
26 drugs (22 approved, 4 experimental)
Ovarian Neoplasms
995 drugs (273 approved, 722 experimental)
Ovarian Torsion
1 approved drug
Primary Ovarian Insufficiency
46 drugs (25 approved, 21 experimental)
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (13)
Phase 3 Indicated Drugs (19)
Phase 2 Indicated Drugs (36)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (5)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
